Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 September 3, 2026 Arvinas to Participate in Upcoming Investor Conferences Read more September 1, 2026 Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Read more August 4, 2026 Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update Read more July 28, 2026 Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026 Read more June 4, 2026 Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease Read more May 29, 2026 Arvinas to Present at Jefferies Global Healthcare Conference Read more May 18, 2026 Arvinas Employees Give Back During Company-wide Impact Day Read more May 12, 2026 Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update Read more May 12, 2026 Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant) Read more May 5, 2026 Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026 Read more
August 4, 2026 Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update Read more
June 4, 2026 Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease Read more
May 12, 2026 Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update Read more
May 12, 2026 Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant) Read more
